2024
Finding Your CAR The Road Ahead for Engineered T Cells
Chen P, Raghunandan R, Morrow J, Katz S. Finding Your CAR The Road Ahead for Engineered T Cells. American Journal Of Pathology 2024, 194: 1409-1423. PMID: 38697513, PMCID: PMC11284763, DOI: 10.1016/j.ajpath.2024.04.002.Peer-Reviewed Original ResearchConceptsChimeric antigen receptorCAR-T cellsAdoptive cellular therapyEngineered T cellsT cellsCellular therapyTumor cellsInfusion of CAR T cellsChimeric antigen receptor T cellsCAR-T cell cytotoxicityCAR-T cell persistenceCAR-T cell therapyT cell persistenceT-cell therapyT cell cytotoxicityTarget tumor antigensCytokine release syndromePathology laboratoryEvaluate side effectsTarget specific antigensTarget antigen identificationTransformative immunotherapyTumor antigensAntigen lossTumor microenvironment
2023
Development of Chimeric Antigen Receptor (CAR) T Cells Targeting MET in Lymphomas and Solid Tumors
Chen P, Raghunandan R, MĂĽschen M, Katz S. Development of Chimeric Antigen Receptor (CAR) T Cells Targeting MET in Lymphomas and Solid Tumors. Blood 2023, 142: 6805. DOI: 10.1182/blood-2023-186161.Peer-Reviewed Original ResearchDiffuse large B-cell lymphomaB-cell lymphomaChimeric antigen receptor T cellsAntigen receptor T cellsLarge B-cell lymphomaReceptor T cellsT cellsLymphoma cell linesHGF/METMET expressionOCI-Ly3CD69 expressionDLBCL cell linesCD19-CARSolid tumorsCell linesAnti-Met monoclonal antibodiesCD19 CAR T cellsNegative diffuse large B-cell lymphomaRefractory B-cell malignanciesLoss of CD19B-cell depletionActivation marker CD69Classic Hodgkin lymphomaJurkat T cells
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply